Prestige Consumer Healthcare (NYSE:PBH) Updates FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 4.500-4.500 for the period, compared to the consensus EPS estimate of 4.440. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

PBH has been the subject of several analyst reports. DA Davidson boosted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. Canaccord Genuity Group lifted their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday. Finally, Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.50.

Prestige Consumer Healthcare Stock Up 0.3 %

Shares of PBH stock traded up $0.29 on Monday, hitting $87.29. 277,886 shares of the stock were exchanged, compared to its average volume of 311,966. The firm has a market capitalization of $4.31 billion, a P/E ratio of 20.44, a price-to-earnings-growth ratio of 2.43 and a beta of 0.50. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $88.36. The business has a 50-day moving average of $79.23 and a 200 day moving average of $75.51. The company has a current ratio of 3.68, a quick ratio of 2.10 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 9,885 shares of the company's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares in the company, valued at $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 in the last 90 days. Company insiders own 1.60% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.